

**Neoadjuvant chemotherapy for breast cancer at Samsung Medical Center From 2016.02 to 2019.08 (N=1840)**

- Hormone receptor (HR)+ Human Epidermal Growth Factor Receptor 2 (HER2)- (N= 539)
- HR+HER2+ (N=328)
- HR-HER2+ (N=371)
- HR-HER2- (Triple negative breast cancer) (N=582)
- Unknown (N=20)

**Neoadjuvant chemotherapy for HER2+ breast cancer (N=699)**

- Neoadjuvant TCHP (Docetaxel, Carboplatin, Herceptin and perjeta) (N=447)
- Neoadjuvant AC (Adriamycin/Cyclophosphamide)-DH (docetaxel/Herceptin) (N=213)
- Neoadjuvant FEC (-DPH) (N=12)
- Others (N=27)

**447 HER2+ early or locally advanced BC with neoadjuvant TCHP**

**S1 Fig.** Patient cohort. BC, breast cancer; TCHP, docetaxel/carboplatin/trastuzumab/per-tuzumab.